In recent years, kidney damage caused by ingestion of Chinese medicinal herbs containing Aristolochic acid (AA) has attracted extensive attention. However, whether the nephrotoxicity of AA is related to NLRP3 inflammasome has not been reported. Hirsutella sinensis (HS) has a certain therapeutic effect on aristolochic acid nephropathy (AAN) and is related to NLRP3 inflammasome. Therefore, this study explores whether HS plays a role in renal injury induced by AA through NLRP3 inflammasome pathway. AA-stimulated renal tubular epithelial cells showed that AA could promote the expression of NLRP3, ASC, and α-SMA, increase the secretion and expression of caspase-1, IL-1β, and IL-18, and inhibit the expression of E-cadherin in a dose- and time-dependent manner. When NLRP3 was down-regulated, the expression of α-SMA and E-cadherin did not change significantly, but significantly blocked the regulation of α-SMA and E-cadherin expression by AA. When AA and HS were added to renal tubular epithelial cells at the same time, the effects of AA on the expression of NLRP3, ASC, caspase-1, IL-1β, IL-18, and α-SMA gradually decreased to the level of control group with the increase of HS dosage. At the same time, HS can reduce the transdifferentiation of renal tubular epithelial cells by inhibiting the activation of NLRP3 inflammasome. These findings will provide important pharmacological references for the treatment of AAN and the clinical application of HS.
This is a preview of subscription content, log in to check access.
This work was supported by grants from the Natural Science Foundation of Ningxia Hui Autonomous Region (Project No. NZ17167), the Traditional Chinese Medicine Science and Technology Program Development Project of Shandong Province (2017-467), and the Doctoral Fund of Linyi People’s Hospital (2016LYBS12).
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
Jadot I, Declèves AE, Nortier J, et al. An integrated view of aristolochic acid nephropathy: update of the literature. Int J Mol Sci. 2017;18(2):297.CrossRefGoogle Scholar
Grollman AP. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen. 2013;54(1):1–7.CrossRefGoogle Scholar
Ko YF, Liau JC, Lee CS, et al. Isolation, culture and characterization of hirsutella sinensis mycelium from caterpillar fungus fruiting body. PLoS One. 2017;12(1):e0168734.CrossRefGoogle Scholar
Zhu ZY, Liu XC, Fang XN, et al. Structural characterization and anti-tumor activity of polysaccharide produced by hirsutella sinensis. Int J Biol Macromol. 2016;82:959–66.CrossRefGoogle Scholar
He L, Ji P, Cheng J, et al. Structural characterization and immunostimulatory activity of a novel protein-bound polysaccharide produced by hirsutella sinensis Liu, Guo, Yu & Zeng. Food Chem. 2013;141(2):946–53.CrossRefGoogle Scholar
Xu XY, Chai JJ, Chen YP, et al. Hirsutella sinensis attenuates aristolochic acid-induced renal tubular epithelial-mesenchymal transition by inhibiting TGF-β1 and snail expression. PLoS One. 2016;11(2):e0149242.CrossRefGoogle Scholar
Yue H, Zhao Y, Wang H, et al. Anti-fibrosis effect for hirsutella sinensis mycelium based on inhibition of mTOR p70S6 K phosphorylation. Innate Immun. 2017;23(7):615–24.CrossRefGoogle Scholar
Huang TT, Lai HC, Ko YF, et al. Hirsutella sinensis mycelium attenuates bleomycin-induced pulmonary inflammation and fibrosis in vivo. Sci Rep. 2015;5:15282.CrossRefGoogle Scholar
Yang Y, Wang H, Kouadir M, et al. Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors. Cell Death Dis. 2019;10(2):128.CrossRefGoogle Scholar
Gauer S, Sichler O, Obermüller N, et al. IL-18 is expressed in the intercalated cell of human kidney. Kidney Int. 2007;72(9):1081–7.CrossRefGoogle Scholar
Turner CM, Arulkumaran N, Singer M, et al. Is the inflammasome a potential therapeutic target in renal disease? BMC Nephrol. 2014;15:21.CrossRefGoogle Scholar
Man YL, Rui HL, Chen YP, et al. Aristolochic acid-induced autophagy promotes epithelial-to-myofibroblast transition in human renal proximal tubule epithelial cells. Evid Based Complement Alternat Med. 2017;2017:9596256.CrossRefGoogle Scholar
Chang SY, Weber EJ, Sidorenko VS, et al. Human liver-kidney model elucidates the mechanisms of aristolochic acid nephrotoxicity. JCI Insight. 2017;2(22):e95978.CrossRefGoogle Scholar
Wen Y, Liu YR, Tang TT, et al. mROS-TXNIP axis activates NLRP3 inflammasome to mediate renal injury during ischemic AKI. Int J Biochem Cell Biol. 2018;98:43–53.CrossRefGoogle Scholar
Wang J, Wen Y, Lv LL, et al. Involvement of endoplasmic reticulum stress in angiotensin II-induced NLRP3 inflammasome activation in human renal proximal tubular cells in vitro. Acta Pharmacol Sin. 2015;36(7):821–30.CrossRefGoogle Scholar
Pozdzik AA, Salmon IJ, Debelle FD, et al. Aristolochic acid induces proximal tubule apoptosis and epithelial to mesenchymal transformation. Kidney Int. 2008;73(5):595–607.CrossRefGoogle Scholar
Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002;17(4):265–77.CrossRefGoogle Scholar
Wang Y, Zhang Z, Shen H, et al. TGF-beta1/Smad7 signaling stimulates renal tubulointerstitial fibrosis induced by AAI. J Recept Signal Transduct Res. 2008;28(4):413–28.CrossRefGoogle Scholar
Tian R, Zhu Y, Yao J, et al. NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res. 2017;357(2):328–34.CrossRefGoogle Scholar
Song S, Qiu D, Luo F, et al. Knockdown of NLRP3 alleviates high glucose or TGFB1-induced EMT in human renal tubular cells. J Mol Endocrinol. 2018;61(3):101–13.CrossRefGoogle Scholar
Huang TT, Chong KY, Ojcius DM, et al. Hirsutella sinensis mycelium suppresses interleukin-1β and interleukin-18 secretion by inhibiting both canonical and non-canonical inflammasomes. Sci Rep. 2013;3:1374.CrossRefGoogle Scholar